- Berichten: 1704
- Lid geworden op: 21 Jan 2013 22:45
- Locatie: Aardbol
- waarderingen: 2502
Word gratis lid op Beursig.com
Discussieer met duizenden andere beleggers en
profiteer van minder advertenties, abonneren op
favoriete onderwerpen en toegang tot de chatbox.
piddybull schreef:Believer,is het niet de helft van die 90 van Novartis ? Hopelijk vergis ik mij eerder.
https://mobile.twitter.com/bdailystocks ... 3968205824
- Forum veteraan
- Berichten: 1928
- Lid geworden op: 27 Jan 2015 12:11
- waarderingen: 1057
Wordt tijd voor een Ablynxje . Dat zal ze leren . Kom er maar in Gilead .
- Forum actieveling
- Berichten: 698
- Lid geworden op: 28 Jan 2018 18:54
- waarderingen: 315
DVM_PhD schreef:believer schreef:Galapagos gaat in 2018 zo een 220-240miljoen euro cash verbranden maar met al hun licentie en mijlpaalbetalingen wordt dit fameus opgevangen in 2018 dit vergeten de analisten.
-Galapagos ontvangt 15miljoen euro van Gilead voor indicatie van Filgo.
-Galapagos ontvangt 95miljoen euro van NOVARTIS.
-Galapagos gaat ... ontvangen voor reuma finch 2?
Iemand die weet hoeveel?
lijkt me eerder 50/50 verdeling tussen GLPG en MOR. Zal dus maar 50% van 95M zijn
Inderdaad 50/50 voor de 95 mijoen maar ook de royalties:
Novartis pays €95M to bag dermatitis drug from Galapagos, MorphoSys
by Nick Paul Taylor | Jul 19, 2018 9:38am
MOR106 will slot into Novartis’ immuno-dermatology pipeline alongside ZPL389. (Wikimedia Commons / Andrew / Flickr)
Novartis is set to pay €95 million ($110 million) upfront for the global rights to Galapagos and MorphoSys’ anti-IL-17C antibody MOR106. The deal positions Novartis to take MOR106 forward in atopic dermatitis and other indications, handing over up to €850 million in milestones as it goes.
Galapagos and MorphoSys discovered MOR106 through a 50-50 joint R&D pact they formed in 2008. The partners focused their efforts on IL-17C in a belief it may act as an amplifier of local inflammation in skin diseases including atopic dermatitis. With phase 1 safety data and preclinical efficacy data in the bag, Galapagos moved the anti-IL-17C antibody into a phase 2 atopic dermatitis trial in May.
Now, Novartis has stepped in. The Swiss pharma will bankroll the phase 2 study and a planned phase 1 trial of a subcutaneous formulation of the drug. MorphoSys and Galapagos will remain involved in the clinical development of MOR106 but Novartis will have full ownership and bear all the costs.
Novartis is paying €95 million upfront for those rights. Galapagos and MorphoSys will split the fee, and however much of the €850 million in milestone are realized, down the middle. The same applies to the low-teens to low-twenties tiered royalties Novartis will pay on net commercial sales if MOR106 comes to market.
MOR106 will slot into Novartis’ immuno-dermatology pipeline alongside ZPL389, an oral H4 receptor antagonist it acquired in the 2016 takeover of Ziarco. Both drugs are being developed as treatments for atopic dermatitis, although the MOR106 program could expand to cover other indications.
“This collaboration with Novartis will enable us to accelerate and broaden the development of MOR106 beyond our current focus on atopic dermatitis and to exploit the potential of MOR106 to the maximum. Data from preclinical models and expression analyses suggest that the target of MOR106 might be involved in other diseases, which justifies expanding the development program," MorphoSys CEO Simon Moroney, Ph.D., said in a statement.
For Galapagos and MorphoSys, the deal validates their belief in the potential of combining their technologies and frees up resources to invest in other assets. The 2008 joint venture sought to marry Galapagos’ targets and other disease-related biology to MorphoSys’ antibody technology. MOR106 is the result of this marriage.
Novartis, MorphoSys and Galapagos have reached an agreement worth as much as $1 billion to market an innovative drug.
Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland.
Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland. PHOTO: ARND WIEGMANN/REUTERS
By Donato Paolo Mancini
July 19, 2018 8:33 a.m. ET | WSJ Pro
Shares in Novartis AG (NOVN.EB), MorphoSys AG (MOR.XE) and Galapagos NV (GLPG.AE) rose on Thursday after the companies said they have reached an agreement worth as much as $1 billion to market an innovative drug.
The agreement is for monoclonal antibody MOR106, which is used mainly for the skin condition atopic dermatitis. The deal is exclusive and covers the commercialization of the compound, which was jointly developed by MorphoSys and Galapagos.
Germany’s MorphoSys and Belgium-based Galapagos will receive an upfront payment of 95 million euros ($111 million), which could rise to EUR850 million ($1 billion) depending on the fulfilment of certain conditions and sales-based targets, the biotechnology companies said.
Novartis will hold the rights to market any products resulting from the agreement signed Thursday, and will bear all future research, development, manufacturing and commercialization costs for the antibody, MorphoSys and Galapagos said.
Novartis, which had sales of $49 billion in 2017, is upping the ante on its transition to a more focused-medicines company with Chief Executive Vas Narasimhan at its helm.
Last month the Swiss pharmaceutical said it will shed its Alcon eyecare unit--which analysts value at about $20 billion--and joined a number of other big-pharma players in exiting antibiotic and antiviral research earlier this month.
The company released a second-quarter earnings statement on Wednesday in which it maintained its outlook for the year.
“[The agreement] looks like a very nice complement to the dermatology franchise being built around Cosentyx, [which buoyed sales in the second quarter]” said an analyst note from Bryan Garnier.
Novartis to Pay as Much as $1 Billion for Skin Drug Rights
By Thomas Mulier
July 19, 2018, 2:29 AM EDT
Updated on July 19, 2018, 3:44 AM EDT
MorphoSys, Galapagos gain on deal for their antibody drug
Novartis to challenge Sanofi with focus on severe eczema
Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as Chief Executive Officer Vas Narasimhan centers the Swiss drugmaker on developing innovative prescription medicines.
Novartis will pay 95 million euros ($111 million) upfront and later payments of up to 850 million euros based on the drug reaching certain regulatory, commercial and sales goals, MorphoSys said in a statement Thursday. The payments will be split 50-50 between Mechelen, Belgium-based Galapagos and Planegg, Germany-based MorphoSys.
Narasimhan needs new medicines to counter the impact of cheaper copycats on older products. The experimental antibody known as MOR106 targets a severe form of eczema and will join a portfolio for skin ailments that includes Cosentyx for psoriasis, on its way to becoming a blockbuster, and Xolair, an asthma drug also prescribed for chronic hives, bolstering Novartis’s dermatology business.
MorphoSys shares surged as much as 5.3 percent in Frankfurt trading, reaching the highest level in 18 years. Galapagos gained as much as 3.9 percent in Amsterdam. Novartis showed little change in Zurich, trading at 81.04 Swiss francs at 9:40 a.m.
“The financials look attractive” for the two biotech developers, Igor Kim, an analyst at Oddo BHF, wrote in a note to clients.
Novartis also agreed to pay royalties to Galapagos and MorphoSys in a range of up to low teens and low 20s as a percentage of sales. MorphoSys raised its 2018 forecasts, with a new sales range that’s about triple the old one and a smaller operating loss.
Atopic dermatitis, which MOR106 aims to treat, is a severe form of eczema that causes the skin to itch, flake, ooze or bleed. It affects an estimated 8 percent of adults and 14 percent of children worldwide, who have few treatment options, according to Novartis. The Swiss company already has an experimental medicine in mid-stage tests against the disease bought in 2016.
The deal means Novartis will be challenging Sanofi and Regeneron Pharmaceuticals Inc., whose drug Dupixent went on sale last year for atopic dermatitis. Novartis could explore the drug’s potential in other indications, a route already traveled by Sanofi and Regeneron, which tested Dupixent on nasal polyps and a form of inflammation of the esophagus, among others.
(Updates with MorphoSys, Galapagos shares in fourth paragraph.)
- Forum actieveling
- Berichten: 600
- Lid geworden op: 07 Apr 2014 08:26
- waarderingen: 185
Wat moet er hier nog allemaal gebeuren voor dat we eens echt doorbreken....overname?